CLINICAL TRIALS AND OBSERVATIONS Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
نویسندگان
چکیده
1Hospices Civils de Lyon and Université Lyon 1, Lyon, France; 2Centre Hospitalier Universitaire de Nice, Nice, France; 3Centre Hospitalier Universitaire de Rennes, Rennes, France; 4Centre Hospitalier Universitaire de Lille, Lille, France; 5Cliniques Universitaires (UCL) de Mont-Godinne, Yvoir, Belgium; 6Centre Hospitalier Universitaire de Montpellier, Montpellier, France; 7Hôpital Henri-Mondor, Assistance Publique-Hopitaux de Paris and Université Paris XII, Paris, France; 8Hôpital Saint-Louis, Assistance Publique-Hopitaux de Paris, Paris, France; 9Centre Hospitalier Universitaire de Nantes, Nantes, France; 10Institut Paoli Calmettes, Marseille, Marseille, France; 11Centre Hospitalier (CH) de Colmar, Colmar, France; 12Institut Gustave Roussy, Villejuif, France; 13Centre Hospitalier Universitaire de Tours, Tours, France; 14Centre Hospitalier Universitaire de Nancy, Nancy, France; 15Centre Léon Bérard, Lyon, France; and 16Centre Hospitalier Universitaire d’Angers, d’Angers, France
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA)
The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by high-dose therapy with autologous stem cell transplantation (ASCT) in treatment-naive patients with advanced follicular lymphoma. Four hundred o...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
Radioimmunotherapy of indolent nonHodgkin lymphoma (NHL) has achieved objective response rates in clinical trials comparable with standard rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, but is relatively underused in routine practice. In this article, we report our clinical experience in 142 consecutive patients who received iodine-131 rituximab radioimm...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma
Idiotype vaccination for follicular lymphoma is primarily being developed as remission consolidation after chemotherapy. We investigated idiotype vaccination as primary intervention for treatmentnaive indolent B-cell lymphoma and in a separate cohort as remission consolidation after chemotherapy to assess immunization-induced immune responses in relation to progression-free survival (German Cli...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 4 schedule
The potential benefits of extended rituximab treatment have been investigated in a randomized trial comparing the standard schedule with prolonged treatment in 202 patients with newly diagnosed or refractory/relapsed follicular lymphoma (FL). All patients received standard treatment (rituximab 375 mg/m2 weekly 4). In 185 evaluable patients, the overall response rate was 67% in chemotherapynaive...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
Rituximab is a chimeric monoclonal antibody that targets B-cell–specific antigen CD20 and an effective treatment for B-cell non-Hodgkin lymphoma. Although it is readily used in clinical practice, the exact mechanism of its antitumor effect is unclear. One potential mechanism involves complement-mediated cytotoxicity. It has been shown that rituximab induces complement-mediated cytotoxicity in f...
متن کامل